Clinical studies have shown that aldosterone and salt are independently related to hypertension, cardiovascular morbidity and mortality. More recently, studies in humans have demonstrated that, similarly to animals, endogenous aldosterone and dietary salt intake have not only separate, but also combined effects to accelerate target-organ deterioration. The aldosterone-salt interaction has important clinical implications, because combined effects of both can be minimized, if not avoided, by reducing salt intake. This interaction could also be interrupted by blocking the effects of aldosterone, with use of mineralocorticoid receptor antagonists, or by reducing aldosterone effects by adrenalectomy, in patients with aldosterone producing adenoma. Furthermore, aldosterone reduction or blockade may reduce salt appetite.
INTRODUCTION
Observational studies and clinical trials performed in general populations indicate that a higher salt intake is associated with development of hypertension, or aggravates hypertension that is already present. A large body of evidence has recognized dietary salt reduction as one of the most important public health interventions to prevent and reduce the incidence of cardiovascular (CV) diseases dependently and independently from its blood pressure (BP) effect. 1 Although some studies 2, 3 have reported data that argue against a public health approach to dietary salt reduction, each has met with criticism regarding methodology and data interpretation.
Aldosterone is a steroid hormone synthesized in the zona glomerulosa of the adrenal cortex and acts as a physiologic regulator of salt and water balance. It promotes sodium retention in the distal renal tubule. Primary aldosteronism (PA), which is now considered to be commonest specifically treatable and potentially curable cause of hypertension, 4 is a disorder in which aldosterone production is inappropriately high for the body's prevailing sodium status, relatively autonomous of the renin-angiotensin system (which is suppressed), and nonsuppressible by sodium loading. While quite elevated levels of aldosterone appear to be harmless when physiologically and appropriately stimulated by a low-salt diet, excessive and autonomous aldosterone production in PA leads to excessive sodium and water retention and consequential increases in BP. 5 In this article, we discuss the effects of aldosterone and dietary salt, separately and in combination, on hypertension and targetorgan deterioration.
ALDOSTERONE AND HYPERTENSION
PA had been considered a rare disease for almost 40 years, until the early 1990s, when our group by applying the aldosterone/ renin ratio to hypertensives (and not just those who were hypokaelemic) was able to report a surprisingly high prevalence of PA. 6 Earlier studies also suggested the high prevalence of PA. [7] [8] [9] Since these reports, multiple studies have confirmed that PA is much more common than had been demonstrated historically with a prevalence ranging from 3 to 32%. 10 The prevalence of PA appears to be related to the severity of the hypertension. Mosso et al. 11 screened over 600 hypertensive patients for PA. The severity of the untreated hypertension was determined for each subject. The overall prevalence of PA was 6.1%. The prevalence, however, increased progressively with the severity of hypertension. In subjects with stage 1 hypertension, the prevalence of PA was only 2%, which was not different from normotensive controls; in subjects with stage 2 hypertension, the prevalence of PA was 8%; and in subjects with stage 3 hypertension, the prevalence was 13%. The results are clinically relevant in demonstrating that the likelihood of PA increases with increasing severity of hypertension such that patients with mild hypertension are at low risk while patients with severe hypertension are a high risk of having PA. PA is particularly common in subjects with resistant hypertension with a prevalence reported to be B20% by several groups worldwide. 12 Other studies have reported evidence of aldosterone excess in patients with resistant hypertension but without definitively confirming the diagnosis of PA. In a prospective study, patients with resistant hypertension received spironolactone (12.5-25 mg per day) in addition to their current treatment. 13 Systolic and diastolic BP reduced by 25 and 12 mm Hg, respectively, after 6 months of treatment. There was a similar BP reduction in patients with compared with those without PA. Furthermore, BP reduction was not predicted by baseline plasma aldosterone or renin levels or by 24-h urinary aldosterone and BP reduction was similar in African-American and whites subjects. In a different study, 279 patients with resistant hypertension, plasma aldosterone, aldosterone to renin ratio and 24-h urinary aldosterone were significantly higher in patients with resistant hypertension than in patients with controlled hypertension (using p2 medications) or normal BP.
14 Brain-type natriuretic peptide and atrial natriuretic peptide were also higher in patients with resistant hypertension, suggesting that intravascular volume expansion may be one mechanism of resistance to treatment.
SERIOUS LONG-TERM CONSEQUENCES OF UNTREATED EXCESS ALDOSTERONE
CV risk Cross-sectional comparisons of patients with PA and hypertensive control patients indicate that the former are at increased risk of having CV disease. Milliez et al. 15 compared PA patients with control (non-PA) patients matched for severity and duration of hypertension. Patients confirmed to have PA were more than 4 times as likely to have had a stroke, 6.5 times as likely to have had a prior myocardial infarction, 2-3 times as likely to have left ventricular (LV) hypertrophy diagnosed by ECG or echocardiogram and more than 12 times as likely to have developed atrial fibrillation ( Table 1) .
In another study, Catena et al. 16 prospectively followed-up 54 patients with PA and 323 patients with primary hypertension with similar BP levels. At baseline, patients with PA were almost five times as likely to have had sustained arrhythmias, 4.4 times as likely to have had a prior cerebrovascular event, and 2.8 times as likely to have coronary heart disease. However, after a mean of 6.4 years of follow-up, the incidence of CV outcomes (myocardial infarction, stroke, any type of revascularization procedure and sustained arrhythmias) were similar between patients with PA, who had been treated with either with adrenalectomy or spironolactone, and patients with primary hypertension treated with nonspecific antihypertensives to achieve BP o140/90 mm Hg. There were no differences between patients with PA treated with adrenalectomy or spironolactone. This study confirmed that patients with PA have increased CV risk independently of BP and, even more importantly, that this excessive CV risk can be reversed with adrenalectomy or mineralocorticoid receptor blockade. These findings argue for early detection of PA among the hypertensive population to facilitate early institution of appropriate, specific surgical or medical management.
Heart
Animal studies have demonstrated that aldosterone excess induces cardiac fibrosis independently of its effects on BP. Weber et al., 17 in 1990, observed diffuse myocardial fibrosis and LV dilatation, and hypertrophy and reduced ejection fraction in a rat model with renovascular hypertension. Myocardial fibrosis occurred not only in the hypertrophied, pressure-loaded LV, but also in the nonhypertrophied and nonpressure-loaded right ventricle, which suggests that the fibrosis occurred in response to humoral, rather than purely hemodynamic factors. Renovascular hypertension is a well-known model of secondary aldosteronism in which angiotensin II and aldosterone are both increased. In order to differentiate the effects of angiotensin II and aldosterone, Weber and Brilla studied rat models of renovascular hypertension and PA. The rat model of PA consisted of uninephrectomized rats treated with aldosterone infusion and a high-salt diet. 18 Rats with renovascular hypertension and those with PA were treated with the mineralocorticoid receptor blocker spironolactone, while another group of rats with PA was treated with the angiotensin converting enzyme (ACE) inhibitor captopril. Spironolactone prevented fibrosis in both models (renovascular and PA) irrespective of the development of LV hypertrophy or hypertension. However, captopril prevented LV hypertrophy and hypertension, but did not prevent fibrosis in the experimental model of PA.
In humans, early clinical trials testing ACE inhibitors in patients with congestive heart failure showed that plasma aldosterone predicted subsequent morbidity and mortality, suggesting a contributory role of aldosterone in the progression of established systolic dysfunction. 19 Based in part on this observation, the RALES (Randomized Aldactone Evaluation Study) was initiated to evaluate the benefit of adding spironolactone to conventional treatment in patients with New York Heart Association class III or IV heart failure with an ejection fraction p35%.
20 Patients (n ¼ 1663) were randomly assigned in a double-blind fashion to receive either spironolactone 25-50 mg or matching placebo while being treated with an ACE inhibitor and a loop diuretic. After B2 years of follow-up, spironolactone decreased mortality by 30% and hospitalizations for congestive heart failure exacerbations by 35%. The reduction in death in the spironolactone arm was attributed mainly to a lower risk of death from progressive heart failure and sudden death. These results were significant in demonstrating activation of the mineralocorticoid receptor as being a major therapeutic target in the pathogenesis of congestive heart failure.
In the EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study), the more selective mineralocorticoid receptor blocker eplerenone was tested in patients with heart failure following acute myocardial infarction. 21 Over 6600 patients with LV ejection fraction p40% were randomized 3-14 days after an acute myocardial infarction to eplerenone 25-50 mg daily or placebo in addition to conventional medical therapy with an ACE inhibitor or angiotensin receptor blocker (ARB), diuretics, b-blockers, and coronary reperfusion therapy as appropriate. Treatment with eplerenone reduced all-cause mortality by 15% and CV death or hospitalization for heart failure, acute myocardial infarction, stroke or ventricular arrhythmia by 13%. These findings extended the results of the RALES study in implicating aldosterone as important mediator of CV risk following myocardial infarction complicated by impairment of systolic function.
In patients with PA, aldosterone induces cardiac changes characterized by LV hypertrophy, increased cavity dimensions and reduced diastolic function that seem to be out of proportion to the elevation of BP. 22 For example, in an Italian study, 26 patients with aldosterone producing adenoma (APA) had significantly increased interventricular septum (IVS) and posterior wall (PW) thicknesses and LV mass indices (LVMI) and decreased early diastolic LV filling when compared with a similar number of patients with primary hypertension matched for age, sex, race, body mass index, casual BP and known duration of hypertension. 23 In a further attempt to assess non-BP-dependent CV effects of aldosterone excess, we studied normotensive subjects with familial hyperaldosteronism type I (FH-I). These patients are characterized by aldosterone overproduction and regulation of aldosterone by adrenocorticotropic hormone (ACTH) rather than by angiotensin II. 24 By genetically testing members of known affected families, the investigators were able to identify and Reduction of aldosterone effects, by adrenalectomy or by mineralocorticoid receptor blockers, seems to reverse aldosterone effects in the heart. In a prospective study, 54 patients with PA, either APA or idiopathic hyperaldosteronism (IHA), and 274 patients with primary hypertension matched for age, gender, body mass index and estimated duration of hypertension were followed for a mean of 6.4 years. 22 Patients with PA were treated with spironolactone (n ¼ 30) or adrenalectomy (n ¼ 24) and patients with primary hypertension had their nonspecific antihypertensive medication treatment adjusted in order to achieve BP o140/90 mm Hg. Patients with PA, at baseline, had greater LV mass (LVM), and a higher prevalence of LV hypertrophy and impaired diastolic function than patients with primary hypertension. In spite of similar BP reduction in patients with PA and primary hypertension, the decrease in LVMI was significantly greater among those patients with PA. At 1 year of follow-up following adrenalectomy or commencement of spironolactone, LVM significantly decreased in adrenalectomized patients only. However, at the end of the study, there was no significant difference in LVM reduction between the surgically and medically treated PA groups. These findings suggest that both surgical and specific medical treatment of PA has greater CV beneficial effects than nonspecific antihypertensive therapy, and that these benefits occur earlier with surgical therapy.
Kidneys
Experimental studies have also demonstrated proinflammatory and profibrotic effects of aldosterone in the kidneys. Using the remnant kidney model, Greene et al. 25 demonstrated that rats treated with the ARB losartan and the ACE inhibitor enalapril showed significant reduction in proteinuria, BP levels and glomerulosclerosis compared with untreated animals. However, infusion of aldosterone to animals treated with losartan or enalapril promoted further increases in proteinuria, hypertension and glomerulosclerosis, demonstrating that aldosterone promotes renal injury independently of angiotensin II. In another study, Rocha et al. 26 implanted time-release pellets of spironolactone in saline drinking stroke-prone spontaneously hypertensive rats, a model of severe hypertension that was not thought to be aldosterone dependent. Despite similar systolic BP levels, animals treated with spironolactone had lower proteinuria and increased survival compared with the control group. Microscopic examination of the kidneys and brain revealed a marked protective effect of spironolactone against the development of malignant nephrosclerotic and cerebrovascular lesions.
Elevated levels of aldosterone are also associated with renal injury in humans. Several observational studies have shown that patients with PA have higher levels of urinary protein excretion compared with patients with primary hypertension. The Primary Aldosteronism Prevalence in Italy (PAPY) study prospectively determined urinary albumin excretion in 490 hypertensive patients, 64 of whom were confirmed as having PA. 27 Patients with PA, whether due to APA or IHA, had higher 24-h urinary albumin excretion rates than the subjects with primary hypertension, in spite of similar BP levels.
The mechanisms related to aldosterone-induced kidney injury seem to be related not only to direct tissue damage, but also related to hemodynamic changes. Urinary protein excretion in patients with aldosterone excess is likely related, at least in part, to intravascular fluid expansion and consequent increases in glomerular filtration rate (that is, hyperfiltration). Sechi et al. 28 prospectively compared the renal function of 50 patients with PA with that in subjects with primary hypertension matched for age, gender, body mass index and estimated duration of hypertension. Patients with PA were followed for a mean of 6.4 years after treatment with adrenalectomy or the mineralocorticoid receptor antagonist spironolactone. In spite of similar BP reduction, the decreases in glomerular filtration rate and albuminuria were significantly greater in the PA group, suggesting that aldosteroneinduced proteinuria in humans is related to intravascular volume expansion and subsequent increases in glomerular filtration rate. Such an effect does not exclude direct toxic effects of aldosterone on glomerular structure, such as inflammation and fibrosis, separate from the hyperfiltration effects.
SALT AND HYPERTENSION
Observational studies and clinical trials performed in general and hypertensive populations indicate that a high dietary salt intake is associated with higher BP. For example, in the INTERSALT study, a multinational evaluation that included more 10 000 normotensive and hypertensive subjects from 52 populations, differences in dietary sodium ingestion of 100 mmol per day were associated with differences in systolic BP of B2.2 mm Hg after adjustment for age, sex, potassium excretion, body mass index and alcohol intake. 29 The positive relation between salt ingestion and level of BP appeared to be stronger in patients with hypertension. Metaanalyses have suggested that low-salt intervention in hypertensive patients decreases systolic and diastolic BP by 3.7-7.0 and 0.9-2.5 mm Hg, respectively. 30 Although the effects of reducing dietary sodium intake on BP levels have been evaluated in the general hypertensive population, few studies have examined the role of dietary salt in patients with resistant hypertension per se. In an interventional study, 12 patients with resistant hypertension were randomized to low-or high-salt diet for 1 week and crossed over to the opposite diet for 1 week after 2 weeks of wash out. 31 Subjects were taking an average of 3.4±0.5 antihypertensive medications and all patients were on a thiazide diuretic (hydrochlorothiazide 25 mg daily) and an ACE inhibitor or an ARB. The low-salt meals provided 50 mmol of sodium per day (2.8 g of salt) and during the high-salt diet, patients received 4250 mmol per day (14.3 g of salt). Mean office systolic and diastolic BP reduced by 22.7/9.1 mm Hg during lowcompared with high-salt diets. The effect of low-salt diet on ambulatory BP was persistent throughout the 24-h period (Figure 1 ). Considering BP reductions that have been observed in our study compared with clinical trials with unselected and untreated hypertensive subjects, our study suggested that patients with resistant hypertension are particularly salt sensitive. Taking into consideration that patients with resistant hypertension are characterized by aldosterone excess, even without definite diagnosis of PA, this suggests that aldosterone and salt may have combined effects at least in this group.
ALDOSTERONE AND SALT
Most experimental studies have indicated that the combined effects of aldosterone excess and high-salt ingestion are necessary for induction of target-organ damage. In one of the earliest demonstrations of this interaction, Brilla and Weber 32 found that uninephrectomized rats with experimentally induced hyperaldosteronism associated with high-sodium diet manifested significant myocardial fibrosis. However, rats treated with aldosterone alone without associated enhanced dietary sodium did not develop fibrosis in the myocardium. A separate group of Salt, aldosterone and hypertension E Pimenta et al rats that received high-sodium diet but no aldosterone also did not develop myocardial fibrosis, suggesting that both chronic hyperaldosteronism and relatively enhanced sodium diet are necessary to induce damage in the heart. Animals treated with angiotensin II and nitric oxide synthesis inhibitor (L-NAME) have also suggested that the vascular damage induced by aldosterone, and which is independent of systolic BP, is partially salt dependent. 33 The mechanisms of aldosterone/salt-induced hypertension and cardiac fibrosis are not fully understood, but aldosterone-independent activation of mineralocorticoid receptors may play an important role. 34 Unlike in animal models of hyperaldosteronism and high dietary salt, an interaction between aldosterone and dietary salt in modulating target-organ damage in humans is less well documented. In a large cross-sectional investigation of 2700 participants from Framingham, subjects in the highest quintile of urinary sodium had twofold higher albuminuria than those in the lowest quintile. 35 Similarly, albuminuria was 21% higher in subjects within the highest quintile of aldosterone compared with those in the lowest quintile. Perhaps surprisingly in this context, plasma aldosterone levels and high urinary sodium excretion did not have additive effects on worsening albuminuria. However, aldosterone status was based on an isolated plasma sampling and urinary sodium excretion was based on a spot urine collection rather than 24-h urinary collection. Furthermore, most of the participants in this study were normotensive and therefore the prevalence of PA is likely to have been low.
A study that evaluated patients with resistant hypertension, a population with a high prevalence of PA, and assessed urine sodium, protein and aldosterone in 24-h urinary collection, demonstrated an interaction between endogenous aldosterone and dietary salt. 36 Among 84 patients with resistant hypertension, 24-h urinary protein increased progressively across tertiles of urinary sodium in patients with hyperaldosteronism, defined as 24-h urinary aldosterone X12 mg per 24 h, but not in patients with normal aldosterone levels ( Figure 2) . Similarly, a positive correlation between urinary protein and urinary sodium was observed in subjects with high urinary aldosterone levels, but not in subjects with normal aldosterone.
The combined effects of aldosterone and salt also promote dilatation and hypertrophy of the heart. A case-control study included 21 patients with confirmed PA and 21 control patients with primary hypertension matched for age, gender, duration of hypertension and 24 h systolic and diastolic BPs. 37 Patients with PA had significantly greater mean LV end diastolic diameter, IVS and PW thicknesses, LVM and LVMI, and end systolic and diastolic volumes than control patients. Urinary sodium significantly positively Salt, aldosterone and hypertension E Pimenta et al correlated with IVS, PW and LVM in patients with PA (Figure 3 ), but not in control patients. In a multivariate analysis, urinary sodium was an independent predictor for LV wall thickness and mass among patients with PA, but not in patients with primary hypertension. The combined effects of aldosterone and salt in determining LV hypertrophy has also been demonstrated in patients with primary hypertension. In a prospective study, plasma aldosterone, urinary sodium excretion and LVMI were measured in 182 never-treated patients. 38 Patients were then commenced on an ACE inhibitor or an ARB, with other agents added if needed for BP control for 3 years. The reduction in LVMI positively correlated with absolute changes in BP, urinary sodium excretion and plasma aldosterone concentration. The analysis by tertiles according to final values of gender-specific urinary sodium excretion and low or high plasma aldosterone concentration showed that LVMI increased progressively in relation to increasing urinary sodium excretion in patients with high aldosterone levels. However, this relation was not found in patients with low aldosterone levels. These results were very similar to our previous results, which showed the combined effects of aldosterone and salt on protein excretion. 36 
SALT APPETITE
Salt appetite, which is a motivated behavioral state that drives animals to seek and ingest foods and fluids that contain sodium, may be stimulated by aldosterone. Aldosterone production by the adrenal glands is markedly stimulated by prolonged sodium deprivation, at least partly independently of glucocorticoids and angiotensin II stimulation. 39 In order to maintain or increase extracellular fluid volume, aldosterone increases sodium retention and stimulates salt appetite.
Aldosterone or other adrenal mineralocorticoids, such as deoxycorticosterone (DOC), when administered in low doses to adrenalectomized animals, restores baseline renal sodium conservation, but reduces sodium appetite. 40 However, high doses of mineralocorticoids significantly stimulate salt ingestion in both adrenal-intact and adrenalectomized animals. 40, 41 For example, Wolf 41 studied the effect of different doses of DOC on sodium chloride intake in intact and adrenalectomized rats. In adrenalectomized rats, low doses of DOC reduced, and high doses stimulated, saline intake. Unoperated rats, however, consumed more sodium chloride and manifested a greater preference for it than adrenalectomized rats for the same dose of DOC. It is of note that hypertonic saline solution was unpalatable to nonoperated rats not given DOC.
The mechanisms by which aldosterone stimulates salt intake are not completely understood, but it is likely related to its action in the brain. Experimental studies have demonstrated that aldosterone stimulates salt appetite by acting centrally. Francis et al. 42 studied the central effects of aldosterone on volume regulation in experimental models of congestive heart failure induced by coronary artery ligation. Spironolactone and ethanol vehicle were administered intracerebroventricularly or intraperitoneally to rats with congestive heart failure and sham-operated rats. Although salt consumption remained similar in sham-operated rats, salt intake significantly increased within the first week and remained high after coronary ligation in animals treated with vehicle intracerebroventricularly or intraperitoneally. Treatment with spironolactone administered intracerebroventricularly or intraperitoneally significantly reduced salt ingestion in rats with congestive heart failure. However, the reduction in salt intake occurred faster with spironolactone administered intracerebroventricularly (within a week) than intraperitoneally (after 3 weeks). These findings suggested that mineralocorticoid receptors in the brain play an important role in determining salt appetite.
We have studied the effects of aldosterone in stimulating salt appetite in humans. Urinary sodium, which reflects salt intake, was measured in 93 patients, before and after adrenalectomy, on the last (fourth) day of fludrocortisone suppression test (FST), using exactly the same protocol, and, in 35 of these patients, we analyzed urinary sodium collected out of hospital. 43 Preliminary results showed that urinary sodium during FST decreased significantly (Po0.0001) from 325 ± 77 mmol per day preoperatively to 273±76 mmol per day postoperatively despite equal salt supplementation. Out-of-hospital urinary sodium fell from 180 ± 57 before surgery to 140 ± 54 mmol per day (P ¼ 0.0022) after surgery. Interestingly, on subgroup analysis, urinary sodium on day 4 of the FST fell significantly only in patients who demonstrated biochemical cure of PA (confirmed by postoperative FST). Our study results suggest that aldosterone excess in humans appears to contribute to salt appetite and its correction by adrenalectomy may have the potential beneficial effect to reduce salt intake in humans.
CONCLUSIONS A large amount of evidence has demonstrated that aldosterone and salt not only have independent effects in inducing hypertension and CV disease, but also that they interact in a synergistic way to further bring about the target-organ deterioration. The clinical implications of the harmful combined effects of aldosterone and salt are related to prevention and treatment of target-organ deterioration. The combined effects of both can be minimized, if not avoided, by reducing salt intake ( Figure 4) . The interaction between raised aldosterone and salt could also be interrupted by blocking the effects of aldosterone, with use of mineralocorticoid receptor antagonists, or by reducing aldosterone effects by adrenalectomy, in patients with APA. Furthermore, aldosterone reduction or blockade may reduce salt appetite.
